Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Two large medical studies from Denmark presented in December 2024 provide more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness.
These two Danish medical studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many.
Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss.
We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss.
And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
The eye side effect non-arteritic anterior ischemic optic neuropathy (NAION) linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs is the focus of an April 2026 medical study report published online by JAMA Network Open.
This medical study report, “GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy“, presents a 2025 analysis of 2017 – 2023 health records from the US Department of Veterans Affairs (VA) done to investigate the rate of this NAION eye side effect that users of Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have reported.
To read more of this article, click below:
When all was said and done, the authors of this 2026 medical study report about NAION concluded:
In this large cohort study, [Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs] use was associated with a modestly increased risk of NAION compared with [sodium-glucose cotransporter-2 inhibitors (SGLT2i) drugs] use. While the absolute risk remains low, the specificity of this finding may warrant heightened vigilance.
NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs is an issue that first came to light in the second part of 2024. For example, two large medical studies from Denmark found that people who used Ozempic had double the risk of developing NAION, which can cause vision loss and blindness.
In the past couple of years, NAION drug injury lawsuits involving Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have been filed against the responsible pharmaceutical companies for their failure to warn patients and doctors about the risk of developing NAION.
For an introduction to the medical and legal aspects of these NAION drug injury lawsuits, here are two relevant Drug Injury Law website links:
- Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
- Zepbound and Mounjaro Eye Side Effect NAION Information Page
We are investigating cases of NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs for patients as drug injury lawsuits seeking legal compensation for their vision loss. We point out that those NAION lawsuits would not be filed against the patients’ doctors because the pharmaceutical company failed to warn about the NAION eye side effect associated with their drug.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
- Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Rybelsus Pancreatitis Warnings and Rybelsus Drug Injury Lawsuits
- A Rybelsus Blood Clots DVT Case
- Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages